The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to investigate the effect of low-dose human growth hormone therapy on immune status and fat morphology.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hvidovre University Hospital
• Collaborator: Pfizer
• Treatments: Hormones

Criteria

Inclusion Criteria:

• Male

• Caucasian race

• Age >21 years, <60 years

• HIV-1 infection

• HAART treated > 12 months

• HIV-RNA < 100 copies/ml

• CD4 count > 200

• Fasting plasma glucose < 6.1 mM

• Stable weight

Exclusion Criteria:

• BMI > 28 kg/m2 and BMI < 18.5 kg/m2

• Wasting or AIDS defining disease

• Severe chronic diseases other than HIV

• Cancer, previous transplantation

• Previous AMI

• Diabetes

• Hormonal substitution therapy

• Lipid lowering or antidiabetic therapy within 3 months

• Abuse of narcotics or alcohol

• Major psychiatric disorders

• Adverse reactions towards Genotropin

• Calcium-ion < 1.15 or > 1.35 mM

• D-vitamin < 19 nM

• TSH < 0.1 or > 10 mIU/l